HELPLINE : +91 22 5025 5025 / 2406 6800 / +91-7506240275  EMAIL : info@acicancer.com

Liquid biopsy gives 100% accuracy in Lung Cancer

In a recent study published in the famous journal JAMA Oncology?, Sacher and colleagues have shown the true value of liquid biopsy. Blood of the patients with advanced lung cancer was used to do droplet digital polymerase chain reaction (ddPCR) assay for detecting common EGFR and KRAS mutations.? Over one year, the study involved 180 patients with advanced disease, including 120 who were newly diagnosed and 60 who had acquired resistance to an EGFR kinase inhibitor. Patients underwent initial blood sampling and immediate plasma ddPCR for EGFR exon 19 del, EGFR L858R, and/or KRASG12X.? All patients also underwent biopsy for tissue genotyping. Tumor genotype included 80EGFR exon 19/L858R mutants, and 25 KRAS G12X mutants.

The median test turnaround time (in business days) for liquid biopsy ddPCR was 3 days (range = 1–7 days). This was significantly shorter than the median turnaround time for tissue genotyping, which was 12 days (range = 1–54 days) for patients with newly diagnosed disease and 27 days (range = 1–146 days) for patients with acquired resistance.

Plasma ddPCR had positive predictive values of 100% for EGFR 19 del, 100% for L858R, 100% for KRAS. Hence, the authors concluded: “Plasma ddPCR detected EGFR and KRAS mutations rapidly with the high specificity needed to select therapy and avoid repeat biopsies in patients with advanced lung cancer.

At Asian Cancer Institute, this is the advantage that we pass on to our patients using the concept of precision oncology.

Facial Features and Genes

With the hospital founder as a leading cardiac surgeon, MedicPress has been able to establish itself as the ultimate destination for diagnosis, treatment, and prevention of all kinds of heart and vascular diseases and their treatment. Here, almost all types of cardiovascular disorders are treated including coronary heart disease, arrhythmia, heart muscle disease, heart failure, heart valve disease, peripheral vascular disease and all kind of defects.

Read more “Facial Features and Genes”

Afatinib superior to Erlotinin in Lung Cancer

Recently details of the LUXLung 8 phase 3 trial became available. This study compared afatinib with erlotinib as second-line treatment for squamous cell carcinoma of the lung.

Afatinib was better with respect to all parameters – median progression-free survival, overall survival and patient-reported quality of life outcome (using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 LC13).

Rates of improved global health status/quality of life (35.7% vs 28.3%; P = .041) and cough (43.4% vs 35.2%; P = .029) were significantly greater with afatinib than erlotinib.?
Afatinib significantly delayed time to deterioration of dyspnea versus erlotinib (2.6 vs 1.9 months; P = .008), with a trend toward delayed time to deterioration of cough with afatinib.

Changes in mean scores over time favored afatinib over erlotinib significantly for cough (P = .0091), dyspnea (P = .0024), and pain (P = .0384).

This is how we improve quality of life and survival for patients with lung cance

Book An Appointment